220 related articles for article (PubMed ID: 37863160)
41. Development of relugolix combination therapy as a medical treatment option for women with uterine fibroids or endometriosis.
Arjona Ferreira JC; Migoya E
F S Rep; 2023 Jun; 4(2 Suppl):73-82. PubMed ID: 37223761
[TBL] [Abstract][Full Text] [Related]
42. Ulipristal acetate for uterine fibroids: 2 years of real world experience in a UK hospital.
Woodhead N; Pounds R; Irani S; Pradhan P
J Obstet Gynaecol; 2018 Aug; 38(6):813-817. PubMed ID: 29526144
[TBL] [Abstract][Full Text] [Related]
43. Goserelin acetate 10.8 mg plus iron versus iron monotherapy prior to surgery in premenopausal women with iron-deficiency anemia due to uterine leiomyomas: results from a Phase III, randomized, multicenter, double-blind, controlled trial.
Muneyyirci-Delale O; Richard-Davis G; Morris T; Armstrong J
Clin Ther; 2007 Aug; 29(8):1682-91. PubMed ID: 17919549
[TBL] [Abstract][Full Text] [Related]
44. Guideline No. 389-Medical Management of Symptomatic Uterine Leiomyomas - An Addendum.
Laberge PY; Murji A; Vilos GA; Allaire C; Leyland N; Singh SS
J Obstet Gynaecol Can; 2019 Oct; 41(10):1521-1524. PubMed ID: 31548041
[TBL] [Abstract][Full Text] [Related]
45. The management of uterine leiomyomas.
Vilos GA; Allaire C; Laberge PY; Leyland N;
J Obstet Gynaecol Can; 2015 Feb; 37(2):157-178. PubMed ID: 25767949
[TBL] [Abstract][Full Text] [Related]
46. Phase III long-term study to evaluate the efficacy and safety of ulipristal acetate in Japanese patients with uterine fibroids.
Osuga Y; Nakano Y; Yamauchi Y; Murakawa H
J Obstet Gynaecol Res; 2021 Sep; 47(9):3269-3278. PubMed ID: 34109697
[TBL] [Abstract][Full Text] [Related]
47. Progestogens or progestogen-releasing intrauterine systems for uterine fibroids (other than preoperative medical therapy).
Sangkomkamhang US; Lumbiganon P; Pattanittum P
Cochrane Database Syst Rev; 2020 Nov; 11(11):CD008994. PubMed ID: 33226133
[TBL] [Abstract][Full Text] [Related]
48. Relugolix/Estradiol/Norethisterone Acetate: A Review in Endometriosis-Associated Pain.
Blair HA
Drugs; 2024 Apr; 84(4):449-457. PubMed ID: 38592603
[TBL] [Abstract][Full Text] [Related]
49. Add-back therapy with GnRH analogues for uterine fibroids.
Moroni RM; Martins WP; Ferriani RA; Vieira CS; Nastri CO; Candido Dos Reis FJ; Brito LG
Cochrane Database Syst Rev; 2015 Mar; 2015(3):CD010854. PubMed ID: 25793972
[TBL] [Abstract][Full Text] [Related]
50. Oral Gonadotropin-Releasing Hormone Antagonists for the Treatment of Uterine Leiomyomas.
Neblett MF; Stewart EA
Obstet Gynecol; 2023 May; 141(5):901-910. PubMed ID: 37103532
[TBL] [Abstract][Full Text] [Related]
51. Long-term medical management of uterine fibroids with ulipristal acetate.
Donnez J; Donnez O; Matule D; Ahrendt HJ; Hudecek R; Zatik J; Kasilovskiene Z; Dumitrascu MC; Fernandez H; Barlow DH; Bouchard P; Fauser BC; Bestel E; Loumaye E
Fertil Steril; 2016 Jan; 105(1):165-173.e4. PubMed ID: 26477496
[TBL] [Abstract][Full Text] [Related]
52. Myfembree for fibroid-associated heavy menstrual bleeding.
Med Lett Drugs Ther; 2021 Aug; 63(1630):121-123. PubMed ID: 34550666
[No Abstract] [Full Text] [Related]
53. Role of ethnicity in treating uterine fibroids with ulipristal acetate.
Murji A; Crosier R; Chow T; Ye XY; Shirreff L
Fertil Steril; 2016 Oct; 106(5):1165-1169. PubMed ID: 27336213
[TBL] [Abstract][Full Text] [Related]
54. Elagolix in the treatment of heavy menstrual bleeding associated with uterine fibroids in premenopausal women.
Ali M; A R S; Al Hendy A
Expert Rev Clin Pharmacol; 2021 Apr; 14(4):427-437. PubMed ID: 33682578
[TBL] [Abstract][Full Text] [Related]
55. Reduction of Heavy Menstrual Bleeding in Women Not Designated as Responders to Elagolix Plus Add Back Therapy for Uterine Fibroids.
Stewart EA; Archer DF; Owens CD; Barnhart KT; Bradley LD; Feinberg EC; Gillispie-Bell V; Imudia AN; Liu R; Kim JH; Al-Hendy A
J Womens Health (Larchmt); 2022 May; 31(5):698-705. PubMed ID: 34582715
[No Abstract] [Full Text] [Related]
56. Efficacy and safety of vilaprisan in women with uterine fibroids: Data from the phase 2b randomized controlled trial ASTEROID 2.
Gemzell-Danielsson K; Heikinheimo O; Zatik J; Poka R; Rechberger T; Hudecek R; Petersdorf K; Ramirez F; Faustmann T; Groettrup-Wolfers E; Seitz C
Eur J Obstet Gynecol Reprod Biol; 2020 Sep; 252():7-14. PubMed ID: 32559602
[TBL] [Abstract][Full Text] [Related]
57. Rapid reduction of adenomyosis coexisting with leiomyoma volume during treatment with Relugolix.
Yamanaka K; Washio K; Uchida A; Sasagawa Y; Nishimoto M; Yamasaki Y; Nagamata S; Terai Y
Gynecol Endocrinol; 2023 Dec; 39(1):2237121. PubMed ID: 37537884
[TBL] [Abstract][Full Text] [Related]
58. A systematic review and meta-analysis of ulipristal acetate for symptomatic uterine fibroids.
Ghonim M; Magdy R; Sabbour M; Ghonim M; Nabhan A
Int J Gynaecol Obstet; 2019 Aug; 146(2):141-148. PubMed ID: 31127621
[TBL] [Abstract][Full Text] [Related]
59. Mifepristone for uterine fibroids.
Tristan M; Orozco LJ; Steed A; Ramírez-Morera A; Stone P
Cochrane Database Syst Rev; 2012 Aug; 2012(8):CD007687. PubMed ID: 22895965
[TBL] [Abstract][Full Text] [Related]
60. Oriahnn for fibroid-associated heavy menstrual bleeding.
Med Lett Drugs Ther; 2021 Apr; 63(1621):51-52. PubMed ID: 33830967
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
